Skip to main content

Table 2 Percentages of different lymphocyte subsets in the CD4+ and CD8+ T cell population, in immune reconstitution inflammatory syndrome patients, clinical progressors and uninfected controls.

From: Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: Beneficial effect of IL-2 and GM-CSF immunotherapy

 

CD4

CD8

 
 

IRIS

p value

HLA-DR

27.4 (16–38.4)

28.7 (24.6–32)

< 0.005/n.s

CD38

77 (70–78.5)

82.6 (75.3–90.7)

n.s/< 0.05

CD38 MFI

1118 (1253-780)

493 (548-297)

< 0.02/< 0.01

Naïve

19.4 (6.9–23.9)

25 (7–42)

< 0.005/n.s

Memory

85 (44–96)

53.8 (37.5–76)

n.s/n.s

 

CP

 

HLA-DR

7.3 (5.4–9.2)

30.5 (22–40)

 

CD38

66 (60.7–71.7)

73 (61.7–80)

 

CD38 MFI

173 (85–211)

133 (105–146)

 

Naïve

35 (30–45)

32 (24.6–42)

 

Memory

59 (54–67)

38 (26–46)

 
 

UC

 

HLA-DR

4 (2.8–5.3)

7.6 (6.9–9.9)

 

CD38

70 (68–75.5)

66 (66–70)

 

CD38 MFI

97 (71–116)

85 (58–87)

 

Naïve

40.8 (40–49)

60.4 (51.2–61.5)

 

Memory

30 (29.2–40)

22 (20.8–30.3)

 
  1. IRIS- Immune reconstitution inflammatory syndrome patients; CP- asymptomatic clinical progressors; UC- uninfected controls. Data are shown as median percentage, and CD38 mean fluorescent intensity (MFI) (interquartile range). p values shown between IRIS and CP patients for CD4/CD8 data respectively.